Form 4 for XTNT Xtant Medical Holdings, Inc.
Accepted 2022-11-17 00:00:00 ET · period of report 2022-11-15 · accession 0001235802-22-000122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-17 | 2022-11-15 | XTNT | Vizirgianakis Stavros G. | Dir | A - Grant | $0.00 | +144.6K | 6.00M | +2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.000001 par value | 2022-11-15 | A | A | 144,639 | $0.00 | 5,995,355 | D | — | — | (F1) These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time, the "2018 Equity Plan"), and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. (F2) Includes 215,415 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the 2018 Equity Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, conditioned upon the reporting person remaining a director of Xtant through the vesting date. |